ALPINE IMMUNE SCIENCES, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-03-15: Study NCT05732402; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Active not recruiting.
- 2021-11-15: Study NCT05034484; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2021-06-22: Study NCT04920383; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2020-06-02: Study NCT04186637; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-03-15 | NCT05732402 An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases | Lead sponsor | Phase 1, Phase 2 | Active not recruiting | Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 72 | 2028-03-02 |
| 2021-11-15 | NCT05034484 A Study of ALPN-303 in Adult Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 72 | 2023-02-27 |
| 2021-06-22 | NCT04920383 ALPN-202 With PD-1 Inhibition in Advanced Malignancies | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumor; Lymphoma | 29 | 2023-02-28 |
| 2020-06-02 | NCT04186637 An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumor; Lymphoma | 62 | 2023-02-28 |
| 2020-05-11 | NCT04227938 ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD | Lead sponsor | Phase 1 | Terminated | Graft Vs Host Disease | 1 | 2020-05-21 |
| 2019-06-12 | NCT03757065 Cell Surface Marker Expression in Autoimmune Diseases | Lead sponsor | Observational | Completed | Systemic Lupus Erythematosus; Sjogren's Syndrome; Multiple Sclerosis; Systemic Sclerosis; Crohn's Disease; Ulcerative Colitis; Inflammatory Myositis | 14 | 2019-10-25 |
| 2019-01-29 | NCT03748836 Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 96 | 2019-11-18 |
| 2016-10 | NCT02934139 MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9) | Lead sponsor | Phase 1 | Completed | Cystic Fibrosis | 32 | 2017-01 |
| 2016-04 | NCT02724527 Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor | Lead sponsor | Phase 2 | Unknown | Cystic Fibrosis | 19 | 2017-04 |
| 2015-11 | NCT02589236 Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation | Lead sponsor | Phase 2 | Completed | Cystic Fibrosis | 138 | 2016-12 |
| 2015-06 | NCT02500667 A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects | Lead sponsor | Phase 1 | Completed | Drug Interaction Potentiation | 15 | 2015-08 |
| 2015-02 | NCT02275936 Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation | Lead sponsor | Phase 1 | Completed | Cystic Fibrosis | 51 | 2015-07 |
| 2014-10 | NCT02227888 PK Study of N91115 in Cystic Fibrosis Patients | Lead sponsor | Phase 1 | Completed | Cystic Fibrosis | 6 | 2015-01 |
| 2014-02 | NCT02013388 MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects | Lead sponsor | Phase 1 | Completed Results posted | Healthy | 49 | 2015-02 |
| 2014-02 | NCT01746784 Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation | Lead sponsor | Phase 1 | Completed Results posted | Cystic Fibrosis | 66 | 2014-05 |
| 2011-04 | NCT01339897 A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects | Lead sponsor | Phase 1 | Completed Results posted | Healthy | 25 | 2011-08 |
| 2011-03 | NCT01316315 Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Asthma | 14 | 2011-12 |
| 2010-08 | NCT01147406 Safety and Tolerability Study of N6022 in Healthy Subjects | Lead sponsor | Phase 1 | Completed Results posted | Healthy | 41 | 2011-06 |